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Hype or Hope?*Howard A. Cohen, MD, Brian P. O’Neill, MDT ranscatheter treatment of valvular diseasehas been performed for more than 3 decades(1). Transcatheter mitral valvuloplasty has
achieved widespread acceptance for patients with
symptomatic mitral stenosis and favorable anatomy
(2). Most recently, transcatheter aortic valve replace-
ment (TAVR) has advanced rapidly and has become
an accepted treatment for patients who are inoper-
able or at high risk for surgical aortic valve replace-
ment (3). The procedure is now being evaluated in
patients with intermediate risk for surgery (“valve
creep”). In the mitral valve (MV) arena, MV percuta-
neous repair for severe mitral regurgitation (MR)
with the MitraClip (Abbott Vascular, Santa Clara, Cal-
ifornia) is now approved for patients with MR due to
“degenerative” MR who are at high surgical risk and is
being rigorously evaluated as well in the United
States (COAPT [Cardiovascular Outcomes Assessment
of the MitraClip Percutaneous Therapy for Heart Fail-
ure Patients With Functional Mitral Regurgitation]
trial, NCT01626079) in patients at high surgical risk
with severe “functional” MR and left ventricular
(LV) dysfunction (4). The device has the CE Mark
and has been used extensively in Europe in both
functional and degenerative MR. Multiple technolo-
gies that mimic surgical MV repair are now being
actively evaluated and are in the early stages of
development, but have not been rigorously evaluated*Editorials published in the Journal of the American College of Cardiology
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this paper.in randomized trials. As of this writing, the pulmonic,
tricuspid, aortic, and mitral valves have all been
replaced by percutaneous techniques (3,5–8).
Transcatheter mitral valve replacement (TMVR) has
not progressed as rapidly as TAVR for several reasons.
First, MV repair (rather than replacement) has been
accepted as preferable whenever possible in degen-
erative MR (9). Second, the MV is signiﬁcantly more
complex, both anatomically and physiologically, than
the aortic valve. Whereas there is no true aortic valve
annulus, the MV annulus is a complex anatomic
structure that has been extensively studied and
imaged and that plays a signiﬁcant physiological role,
along with the leaﬂets, chordae, and papillary mus-
cles, in maintaining the integrity and function of the
MV, as well as of the left ventricle (10). Off-label use of
percutaneous aortic valves has been successfully
utilized in the MV position to treat degenerated bio-
prosthetic valves, as well as failed mitral ring repairs
(7,8). This strategy is facilitated by the rigid annulus of
the bioprosthetic valve or surgical ring, which presents
a platform for the valve-in-valve. In addition, there are
several reports of TMVR using balloon-expandable
valves in patients with severe calciﬁc mitral disease
who were thought to be inoperable by standard tech-
niques (11,12). As with TAVR, the calciﬁc disease may
be important in these patients, providing a rigid plat-
form to anchor the prosthetic valve. The native non-
calciﬁed MV has no such rigid ring to anchor a
percutaneous valve, although patented technology
has now been developed that may provide such a
platform or anchor for a percutaneous device. Any
percutaneousMV replacement technology will need to
incorporate a similar type of platform or technology to
achieve secure positioning of the valve.
Cheung et al. (13) recently reported the ﬁrst-in-man
series of transapical MV replacement using the Tiara
device (Neovasc, Richmond, British Columbia), with
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1021excellent results in 2 patients with severe MR and
depressed LV function. In this issue of the Journal,
the authors report their initial experience with
the FORTIS valve (Edwards Lifesciences, Irvine,
California) in 3 patients with severe functional MRSEE PAGE 1011(14). Their report is the ﬁrst to provide a longer-term
follow-up indicating not only the feasibility of the
procedure, but also the efﬁcacy and safety at
6 months. Patients were evaluated by a heart team
and were declined for surgery due to their comor-
bidities. The valve was delivered successfully in all
patients via a transapical approach. There was less
than minor residual leak in all patients, and all were
discharged after the successful procedure. At follow-
up, transmitral and left ventricular outﬂow tract
(LVOT) gradients in all patients were acceptable, and
all showed improvement in New York Heart Associa-
tion functional classiﬁcation at 3 and 6 months.
The authors are to be congratulated for their
contribution to the ﬁeld of TMVR in this group of
high-risk patients. Their report highlights several
important aspects of the procedure that will apply to
all future valve designs. Computed tomography will
continue to play a vital pre-planning role in accurate
sizing of the MV annulus to strike a delicate balance
between undersizing (and paravalvular leak) and
oversizing (and LVOT obstruction) (15). New imaging
software packages will allow for computed tomogra-
phy coregistration and improved online echocar-
diographic guidance as well. Given the complex
interaction between the aortic and mitral valves,
3-dimensional printing may also serve an important
role in modeling the heart and allowing insertion of
differently sized “model valves” before the actual
procedure, as demonstrated in caval valve implant for
severe tricuspid regurgitation (16). Transesophageal
echocardiography will continue to be critical to the
success of the procedure by conﬁrming accurate
transapical access to maintain coaxiality of the valve
system and assessing, in real time, residual MR and
gradients across the MV and LVOT (9,13).
As the ﬁeld matures, several challenges will
need to be addressed. Current technology requiresinsertion of large delivery sheaths via the LV apex.
As many nonsurgical candidates already have severe
LV dysfunction, transseptal delivery systems have
the potential to decrease the morbidity and improve
the safety of these procedures. Furthermore, these
devices will undoubtedly become smaller and more
user friendly, thus facilitating their delivery. In those
patients in whom transapical delivery is preferable,
novel closure device systems are currently in devel-
opment for percutaneous closure. Finally, we must
remember that this report is truly of a short-term
follow-up and that we have much to learn regarding
the safety of this approach in terms of the durability
of the bioprosthesis, the alignment and continued
security of the device, the potential for erosion, the
possibility of outﬂow tract obstruction, and the need
for anticoagulation over the long term (9). Recently,
the U.S. trial of the FORTIS valve was halted due to
cases of valve thrombosis, emphasizing the need for
continued research regarding anticoagulation and
biocompatibility.
This is an exciting time in the evolutionary and
revolutionary treatment of valvular heart disease,
with an opportunity to improve the lives of our pa-
tients. As noted by many investigators, patients are
frequently being denied treatment because they are
thought to be “too sick” (9). If nothing else, what we
have learned from the TAVR experience is that we can
treat these very sick patients, improve the quality of
their lives, and do this in a cost-effective fashion. We
should not lose sight of the fact that MV surgery
(replacement and repair) by experienced operators is
a very mature “art form” that provides effective
treatment for our patients (17) and that will set a very
high bar for any percutaneous therapy that is devel-
oped. It is reasonable at the outset, therefore, to
consider TMVR in those patients who need MV
replacement, but who are thought by the multidisci-
plinary team to be at high risk for surgery.
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